OR WAIT 15 SECS
Company and People Notes: Wyeth and Ambrx form development pact; Elite Pharma appoints CEO and CSO; more...
AstraZeneca (London) and Nektar Therapeutics (San Carlos, CA) signed a license agreement for two drug development programs: NKTR-118, a late-stage investigational product designed for the treatment of opioid-induced constipation, and NKTR-119, which is intended to deliver products for the treatment of pain without constipation side effects. Both programs were developed by Nektar, using its proprietary small-molecule advanced polymer conjugate technology platform. Nektar will receive an upfront payment of $125 million for both NKTR-118 and NKTR-119; for the NKTR-118 program specifically, up to $235 million in regulatory milestones, up to $375 million in sales milestones, and double-digit royalty payments; and for NKTR-119, the company is eligible to receive development and sales milestone payments and double-digit royalties on sales.
Avid Bioservices (Tustin, CA), a contract manufacturer, and Boehringer Ingelheim (Ingelheim, Germany) entered into a production-alliance agreement that makes Avid an approved member of Boehringer Ingelheim’s global Production Alliance Network PAN Biologics. The Production Alliance Network program is set up to provide the partners’ customers with a broader range of contract services, according to an Avid press release.
Chiral Technologies (West Chester, PA), a provider of chiral chromatography columns, signed a sales agreement with LEACSA (Mexico City), distributor of separation systems. Under the agreement, LEACSA will serve as Chiral Technologies’ master sales distributor in Mexico.
The board of directors of Facet Biotech (Redwood City, CA) advised its stockholders to take no action in response to the announcement by Biogen Idec’s (Cambridge, MA) unsolicited conditional tender offer to acquire all of Facet Biotech's outstanding shares of common stock for $14.50 per share in cash. Facet’s board says it will review the offer and advise stockholders within 10 business days, according to a Sept. 21, 2009 press release.
Icagen (Research Triangle Park, NC) announced a one-year extension to an existing collaboration and licensing agreement with Pfizer (New York) aimed at discovering, developing, and commercializing compounds that modify three specific sodium-ion channels as new potential treatments for pain and related disorders. Pfizer will provide approximately $5 million in funding to Icagen over the next year, and Icagen remains eligible to receive approximately $359 million in research, development, regulatory, and commercialization milestones for each product, as well as royalties based upon product sales.
Merck & Co. (Whitehouse Station, NJ) and the charity Wellcome Trust (London) formed Hilleman Laboratories, which will use a not-for-profit operating model to develop and deliver vaccines to low-income countries. Hilleman Laboratories will be based in India and will seek to develop vaccines in areas of unmet need, as well as to optimize vaccines to increase their impact when resources are limited. The CEO will be Altaf A. Lal, who spent 20 years working for the National Center for Infectious Diseases at the Centers for Disease Control and Prevention, and is currently Health Attache and Department of Health and Human Services Regional Representative for South Asia at the US embassy in New Delhi, India.
Wyeth Pharmaceuticals (Collegeville, PA), a division of Wyeth and Ambrx (La Jolla, CA), a biopharmaceutical company, formed an alliance to discover, develop, and commercialize protein-drug candidates for three undisclosed targets in multiple therapeutic areas. Ambrx anticipates earning an upfront payment, as well as preclinical, clinical, regulatory, and commercial milestone payments and royalties on sales.
American Pacific (Las Vegas, NV), a manufacturer of active pharmaceutical ingredients and intermediates, announced that John R. Gibson, chairman of the board of directors and CEO, will retire as CEO, effective December 31, 2009. He will be succeeded by Joseph Carleone, who currently serves as president and chief operating officer. Gibson will retain his role as chairman of the board.
BioMicro Systems (Salt Lake City, UT), a developer of biological research products based on its proprietary microfluidic and microarray technologies, appointed Rob Parry president and chief operating officer. Parry will be responsible for expanding sales of the MAUI Microarray Product Suite, as well as launching a new line of products for the cytogenetics market.
Eli Lilly and Company (Indianapolis, IN) promoted David Ricks, currently general manager of Lilly China, to president of Lilly USA, LLC. Ricks will succeed Enrique Conterno, who was named leader of Lilly's new Diabetes Business Unit as part of a company reorganization announced Sept. 14, 2009. Ricks will assume his new role beginning Nov. 1, 2009, and Eric Baclet, currently vice-president of marketing over global neuroscience brands, will succeed Ricks to lead Lilly China.
Elite Pharmaceuticals (Northvale, NJ) appointed Jerry I. Treppel as its CEO, and Ashok G. Nigalaye, as its chief scientific officer. Treppel has served on Elite's board of directors since October 2008 and has been chairman since November 2008. Nigalaye has served on the board since June 2009.
Ryan Titmas was named vice-president of sales for Sartorius Mechatronics (Bohemia, NY). Titmas will be responsible for the following brands: Sartorius Lab, Industrial, and Process Weighing products including the Denver and Acculab brands.
Variation Biotechnologies (Cambridge, MA) appointed Jeff Baxter as CEO and as a member of the board of directors. Baxter replaces Francisco Diaz-Mitoma, a founder of the company who will remain a board member and will transition to chief scientific officer and president of the company’s Canadian operations. Baxter will be based at the company's new US headquarters in Cambridge, Massachusetts.